New test to learn more about perimenopause, an epigenetic reprogramming

Perimenopause, affecting over 1 billion women globally, remains one of the most underserved areas of healthcare. Standard approaches often rely on years of trial and error, leaving women and their doctors frustrated, unsupported, and at risk of preventable age-related conditions. Willbe’s proprietary sciences — Hormogenomics™ and Hormogenetics™ — deliver a precision solution by predicting how a woman’s body will metabolize and respond to declining hormones, long before symptoms take hold.

Perimenopause, an epigenetic reprogramming event

Willbe, the pioneering female health and longevity platform founded by Forbes 30 Under 30 entrepreneur and biomedical scientist Yulia Mintchin, announces the launch of its flagship genetic innovation, FemGene the world’s first test built to decode how women uniquely experience perimenopause and respond to bioidentical hormone therapy (BHRT).

Through its Hormonal Archetypes™ methodology, Willbe classifies women into clear hormonal archetypes rooted in genetics that guide treatment pathways with accuracy and confidence. Unlike traditional one-size-fits-all care, this personalized approach enables faster relief, longer adherence to BHRT, and ultimately supports healthier, longer lives for women.

“Perimenopause is not just declining hormones — it’s an epigenetic reprogramming event. The body says: the way I used to run no longer works. Whether a woman thrives or struggles is written in her genes. As hormones decline, gene expression shifts — driving how she ages, repairs, and restores. That’s why women on the same HRT dose can have completely different outcomes. By decoding each woman’s genetic blueprint, we can predict her hormonal journey and deliver targeted solutions from day one,” said Yulia Mintchin, Founder and CEO of Willbe. “This is the moment women move beyond trial-and-error healthcare into precision longevity medicine”

Willbe bridges functional and traditional medicine, offering women access to advanced testing, personalised longevity protocols, and expert support. The launch of FemGene® positions Willbe as the category leader in female hormonal health and longevity, bridging hormones, skin health and preventative medicine.

Willbe is a UK-based female health and longevity company, redefining perimenopause as the front door to female longevity. Combining genetics, hormone testing, and bioidentical HRT, Willbe’s Hormogenetics™ platform offers predictive, personalized healthcare that empowers women to extend their health-span. Willbe’s mission is to transform female health from reactive to preventative and to save billions of women the cost of unnecessary and absolutely preventable suffering.

https://www.mywillbe.co.uk/

https://www.linkedin.com/in/yuliamintchin/

https://www.instagram.com/my_willbe/

See more breaking stories here.